The U.S. FDA is stepping up inspections of drug-industry facilities in India and their compliance with manufacturing standards. The agency is training and enrolling more drugs investigators in the second-biggest supplier of finished dose treatments to the U.S. "Having these additional inspectors in-country will assist the agency in meeting our legislative mandates," U.S. FDA spokesman Christopher C. Kelly said.

Related Summaries